← All indications
Polycystic Kidney, Autosomal Dominant
Kidney disorders with autosomal dominant inheritance and characterized by multiple CYSTS in both KIDNEYS with progressive deterioration of renal function.
Drugs by status
Phase 4 trials (9)
Phase 3 trials (11)
Phase 2 trials (17)
Phase 1 trials (17)
Other trials (3)
Organizations
Organization Involved with Phase 4 Indications (7)
Organization Involved with Phase 3 Indications (23)
- Genzyme
- Sanofi
- Ipsen
- Reata Pharmaceuticals, Inc.
- National Center for Research Resources (NCRR)
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
- Aarhus University
- Azienda Ospedaliero-Universitaria Consorziale
- Katholieke Universiteit Leuven
- Radboud University
- University of Groningen
- Yale University
- University of Zurich
- Mayo Clinic
- University of Naples Frederico II
- University of Vienna
- Leiden University
- ASL Bari
- Mario Negri Institute
- Second Military Medical University
- University of Paris
- Erasmus University Rotterdam
- Palladio Biosciences
Organization Involved with Phase 2 Indications (15)
Organization Involved with Phase 1 Indications (1)
Organization Involved with Other Experimental Indications (2)